Ravi P

Open figure viewer Topics: covid-19, nirmatrelvir, ritonavir, pharmacokinetics Nirmatrelvir/ritonavir is authorized for emergency use by the United States Food and Drug Administration in adolescents aged at least 12 years and at least 40 kg based on pharmacokinetic/pharmacodynamic modeling demonstrating that the approved adult regimen results in comparable blood concentrations of nirmatrelvir/ritonavir in children. Pediatric clinical data are limited.